RedHill Biopharma Ltd - ADR RDHL shares are trading higher by 68 cents (8 percent) at $10.15 in Wednesday's session.
The catalyst for the rally is positive Phase III results with BEKINDA for acute gastroenteritis.
See Also: RedHill Biopharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
After a higher open, RedHill retreated but found support just above the top of Tuesday's range ($9.71) at $9.80 and resumed its move higher. The ensuing rally has taken the stock to $10.64, which coincides with it April 21 high of $10.64.
It's now attempting to post its first close over $10.00 since May 23, when it ended that session at $10.11.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.